This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
PGA-based lipid nanoparticles co-delivering peptide antigen and TLR7/8 agonist activated antigen-specific T cells in mice via both subcutaneous and IV routes.
Why it matters
A universal platform for co-delivering any peptide antigen with immune boosters could accelerate personalized cancer vaccine development.
The numbers in context
PGA-Ag + PGA-IMDQ co-delivered; ionizable lipid LNP; SC and IV routes; innate immune cell uptake confirmed; Ag-specific T cells induced
How the study worked
Lab and animal study. Conjugated peptide antigen and IMDQ adjuvant to PGA. Condensed into lipid nanoparticles with ionizable lipid. Tested uptake by immune cells and T-cell activation in mouse models.
Who was studied
Mouse models (in vivo immunization studies)
What this study cannot tell us
Animal study in mice. Efficacy against actual tumors not tested. Human immune responses may differ. Specific peptide antigens tested were limited.
Read the original research
Lipid-Polyglutamate Nanoparticle Vaccine Platform.
ACS applied materials & interfaces, 13(5), 6011-6022
Citation
Van Lysebetten, Dorien; Malfanti, Alessio; Deswarte, Kim; Koynov, Kaloian; Golba, Bianka; Ye, Tingting; Zhong, Zifu; Kasmi, Sabah; Lamoot, Alexander; Chen, Yong; Van Herck, Simon; Lambrecht, Bart N; Sanders, Niek N; Lienenklaus, Stefan; David, Sunil A; Vicent, María J; De Koker, Stefaan; De Geest, Bruno G. (2021). Lipid-Polyglutamate Nanoparticle Vaccine Platform.. ACS applied materials & interfaces, 13(5), 6011-6022. https://doi.org/10.1021/acsami.0c20607